7-(7-Amino-5-azaspiro[2.4]heptan-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid--water (2/3)

개요The fluoroquinolone antibacterial agent sitafloxacin hydrate was developed by Daiichi Sankyo and was approved and launched last year in Japan. Sitafloxacin’s mode of action is through inhibition of DNA gyrase and topoisomerase IV. It is indicated for the treatment of inflammatory infections such as laryngopharyngitis, adenoiditis, acute bronchitis, pneumonia, secondary infections due to chronic respiratory lesions, cystitis, pyelonephritis, urethritis, cervicitis, otitismedia, sinusitis, periodontitis, and pericoronitis and jaw inflammation. Due to its broad spectrum of potent antibacterial activity, sitafloxacin is expected to be clinically effective in treating severe cases of bacterial infection, relapse/recrudescence of infection and infections in which resistant bacteria are suspected to be the cause.

용도Sitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone antibiotic. It is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in